NO20031742L - HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfa - Google Patents
HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfaInfo
- Publication number
- NO20031742L NO20031742L NO20031742A NO20031742A NO20031742L NO 20031742 L NO20031742 L NO 20031742L NO 20031742 A NO20031742 A NO 20031742A NO 20031742 A NO20031742 A NO 20031742A NO 20031742 L NO20031742 L NO 20031742L
- Authority
- NO
- Norway
- Prior art keywords
- ribavirin
- combination therapy
- interferon alfa
- pegylated interferon
- hcv combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24155700P | 2000-10-18 | 2000-10-18 | |
PCT/US2001/032434 WO2002032414A2 (en) | 2000-10-18 | 2001-10-16 | Ribavirin-pegylated interferon alfa hcv combination therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20031742D0 NO20031742D0 (no) | 2003-04-15 |
NO20031742L true NO20031742L (no) | 2003-06-17 |
Family
ID=22911172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20031742A NO20031742L (no) | 2000-10-18 | 2003-04-15 | HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfa |
Country Status (13)
Country | Link |
---|---|
US (1) | US20020127203A1 (zh) |
EP (1) | EP1326594A2 (zh) |
JP (1) | JP2004511513A (zh) |
CN (1) | CN1516599A (zh) |
AU (1) | AU2002213343A1 (zh) |
BR (1) | BR0114636A (zh) |
CA (1) | CA2425522A1 (zh) |
HK (1) | HK1052878A1 (zh) |
HU (1) | HUP0301444A3 (zh) |
MX (1) | MXPA03003456A (zh) |
NO (1) | NO20031742L (zh) |
WO (1) | WO2002032414A2 (zh) |
ZA (1) | ZA200302525B (zh) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
YU92202A (sh) | 2000-05-26 | 2006-01-16 | Idenix (Cayman) Limited | Metode i smeše za lečenje flavi virusa i pesti virusa |
EP1461067A1 (en) * | 2001-12-07 | 2004-09-29 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
NZ533808A (en) * | 2001-12-21 | 2005-03-24 | Biopartners Gmbh | Ribavirin granulate for producing coated tablets |
AU2003248748A1 (en) * | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
CN104193791A (zh) | 2002-06-28 | 2014-12-10 | 埃迪尼克斯医药公司 | 用于治疗黄病毒感染的修饰的2’和3’-核苷前药 |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
CN1849142A (zh) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′-支链核苷和黄病毒突变 |
KR20050110611A (ko) * | 2002-12-23 | 2005-11-23 | 이데닉스 (케이만) 리미티드 | 3'-뉴클레오사이드 프로드럭의 생산 방법 |
EP3521297B1 (en) | 2003-05-30 | 2021-12-22 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
CA2535451A1 (en) * | 2003-08-13 | 2005-02-24 | Howard J. Smith & Associates Pty Ltd. | Method of treating viral infections |
CA2554188A1 (en) * | 2004-01-23 | 2005-08-04 | Elan Pharmaceuticals, Inc. | Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids |
JP2008503562A (ja) * | 2004-06-23 | 2008-02-07 | イデニクス(ケイマン)リミテツド | フラビウイルス科による感染症を治療するための5−アザ−7−デアザプリン誘導体 |
EP1795206A4 (en) | 2004-08-11 | 2009-07-22 | Chugai Pharmaceutical Co Ltd | MEDICAMENT FOR THE TREATMENT OF HCV OR THE PREVENTION OF HCV INFECTION |
ES2769377T3 (es) | 2004-09-14 | 2020-06-25 | Gilead Pharmasset Llc | Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo |
EP1976382B1 (en) | 2005-12-23 | 2013-04-24 | IDENIX Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
WO2007132882A1 (ja) * | 2006-05-16 | 2007-11-22 | Tokyo Metropolitan Organization For Medical Research | Hcv感染症を治療または予防するための医薬組成物 |
ES2402589T3 (es) * | 2006-07-07 | 2013-05-07 | Meiji Seika Pharma Co., Ltd. | Agente profiláctico o terapéutico para enfermedad viral |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US8793074B2 (en) * | 2007-06-21 | 2014-07-29 | Saint Louis University | Sequence covariance networks, methods and uses therefor |
TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
EP2610343A3 (en) | 2008-11-26 | 2013-09-25 | Chugai Seiyaku Kabushiki Kaisha | Method for designing siRNA and oligoribonucleotides inhibiting HCV |
NZ593648A (en) | 2008-12-23 | 2013-09-27 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
PA8855801A1 (es) | 2008-12-23 | 2010-07-27 | Sintesis de nucleosidos de purina | |
WO2010075517A2 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Nucleoside analogs |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
JPWO2011001897A1 (ja) * | 2009-06-30 | 2012-12-13 | Meiji Seikaファルマ株式会社 | 難治性のc型慢性肝炎の治療のための薬剤及び方法 |
US20120177601A1 (en) * | 2009-07-02 | 2012-07-12 | The Usa As Represented By The Secretary Of The Department Of Veterans Affairs | Treatment of hepatitis c virus infections |
ES2551944T3 (es) | 2010-03-31 | 2015-11-24 | Gilead Pharmasset Llc | (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2H)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato de isopropilo cristalino |
CN103153311A (zh) | 2010-06-03 | 2013-06-12 | 药品循环公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
JP6069215B2 (ja) | 2010-11-30 | 2017-02-01 | ギリアド ファーマセット エルエルシー | 化合物 |
DE202012013074U1 (de) | 2011-09-16 | 2014-10-29 | Gilead Pharmasset Lcc | Zusammensetzungen zur Behandlung von HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
ES2527510T1 (es) | 2011-10-21 | 2015-01-26 | Abbvie Inc. | Métodos para el tratamiento del VHC que comprenden al menos dos agentes antivirales de acción directa, ribavirina pero no interferón |
DE112012003457T5 (de) | 2011-10-21 | 2015-03-12 | Abbvie Inc. | Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV) |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
EP2877598A1 (en) | 2012-07-24 | 2015-06-03 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
JP2015536950A (ja) | 2012-11-02 | 2015-12-24 | ファーマサイクリックス,インク. | Tecファミリーキナーゼ阻害剤アジュバント療法 |
CN104144682A (zh) | 2013-01-31 | 2014-11-12 | 吉利德法莫赛特有限责任公司 | 两个抗病毒化合物的联用制剂 |
ES2900570T3 (es) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
CA2942528A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics Inc. | Phospholipase c gamma 2 and resistance associated mutations |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
WO1997016204A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
ES2172288T3 (es) * | 1998-05-15 | 2002-09-16 | Schering Corp | Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c. |
US6277830B1 (en) * | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
US6403564B1 (en) * | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
CA2354536A1 (en) * | 1998-12-18 | 2000-06-29 | Schering Corporation | Ribavirin-pegylated interferon alfa induction hcv combination therapy |
US6824768B2 (en) * | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
EP1140142A2 (en) * | 1998-12-22 | 2001-10-10 | Schering Corporation | Treatment of hepatitis c virus infections with interleukin-10 |
US6635646B1 (en) * | 1999-05-04 | 2003-10-21 | Schering Corporation | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy |
WO2001081359A1 (en) * | 2000-04-20 | 2001-11-01 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
US6673775B2 (en) * | 2001-04-18 | 2004-01-06 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
WO2003024461A1 (en) * | 2001-09-20 | 2003-03-27 | Schering Corporation | Hcv combination therapy |
-
2001
- 2001-10-16 AU AU2002213343A patent/AU2002213343A1/en not_active Abandoned
- 2001-10-16 MX MXPA03003456A patent/MXPA03003456A/es unknown
- 2001-10-16 EP EP01981718A patent/EP1326594A2/en not_active Withdrawn
- 2001-10-16 US US09/981,215 patent/US20020127203A1/en not_active Abandoned
- 2001-10-16 WO PCT/US2001/032434 patent/WO2002032414A2/en not_active Application Discontinuation
- 2001-10-16 BR BR0114636-0A patent/BR0114636A/pt not_active IP Right Cessation
- 2001-10-16 JP JP2002535652A patent/JP2004511513A/ja active Pending
- 2001-10-16 CN CNA018176038A patent/CN1516599A/zh active Pending
- 2001-10-16 HU HU0301444A patent/HUP0301444A3/hu unknown
- 2001-10-16 CA CA002425522A patent/CA2425522A1/en not_active Abandoned
-
2003
- 2003-03-31 ZA ZA200302525A patent/ZA200302525B/en unknown
- 2003-04-15 NO NO20031742A patent/NO20031742L/no unknown
- 2003-07-17 HK HK03105160.0A patent/HK1052878A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2002032414A3 (en) | 2003-04-03 |
US20020127203A1 (en) | 2002-09-12 |
CA2425522A1 (en) | 2002-04-25 |
EP1326594A2 (en) | 2003-07-16 |
HK1052878A1 (zh) | 2003-10-03 |
HUP0301444A2 (hu) | 2003-11-28 |
AU2002213343A1 (en) | 2002-04-29 |
BR0114636A (pt) | 2004-02-10 |
WO2002032414A2 (en) | 2002-04-25 |
MXPA03003456A (es) | 2003-07-14 |
NO20031742D0 (no) | 2003-04-15 |
CN1516599A (zh) | 2004-07-28 |
JP2004511513A (ja) | 2004-04-15 |
ZA200302525B (en) | 2004-07-21 |
HUP0301444A3 (en) | 2007-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20031742L (no) | HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfa | |
NO20005755L (no) | Kombinasjonsterapi omfattende ribavirin og interferon-<alfa> hos antivirusbehandlingsnaive pasienter med kronisk hepatitt C- infeksjon | |
DK1087778T3 (da) | Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C | |
PT1576138T (pt) | 2'-metil-nucleósidos em combinação com interferão e mutação de flaviviridae | |
NO20052363D0 (no) | Interferon-alfa polypeptider og konjugater | |
NO992373L (no) | Forlenget anestesi i ledd og kroppshulrom | |
DK1404809T3 (da) | Forbedrede hudsubstitutter og anvendelser deraf | |
NO20033296D0 (no) | Baerer med fastoffibrinogen og fastofftrombin | |
HK1154498A1 (en) | Remodelling and glycoconjugation of interferon-alpha(ifna) | |
NO20014560D0 (no) | Quinasoliner og terapautisk anvendelse derav | |
DE60017241D1 (de) | Unterwasserbehandlungsanordnung und -verfahren | |
ITTO20020564A0 (it) | Serbatoio a tenuta stagna e termicamente isolante a spigoli longitudinali obliqui. | |
NO20015367D0 (no) | Pegylert interferon <alfa>-CCR5-antagonist-kombinasjons HIV- terapi | |
DE69931196D1 (de) | Magnetisch betätigter schwimmschalter | |
IT250493Y1 (it) | Sedia rigida e impilabile | |
NO20034432D0 (no) | Interferon gamma polypeptidvarianter | |
IS5777A (is) | Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess | |
PL363181A1 (en) | Modified interferon alpha with reduced immunogenicity | |
NO20020919L (no) | Irenprotein, dets fremstilling og anvendelse | |
DE60021857D1 (de) | Synergistische kombination enthaltend ein interferon und ein nucleosid mit antiflaviviralem und antirhabdoviralem effekt | |
DK1232416T3 (da) | Lukker med frem- og tilbagegående rem og dobbelt motor | |
SI1311279T1 (sl) | Zdravljenje hepatitisa c s timozinom, interferonom in ribavirinom | |
FIU990493U0 (fi) | Sovitelma kiukaan yhteydessä ja kiuaskivi | |
DE10060499B4 (de) | Spinnaker mit Klettverschlüssen | |
HU0101661D0 (en) | Improved armored tank with inncreased fire-powen and mobility |